GNFTF - Gilead Is Gearing Release Of NASH Results Soon But Other Deals Are Still Rolling In
Gilead Sciences (GILD) is getting ready to release NASH results in the 1st half of 2019. This will be from studies dealing with selonsertib to treat patients with NASH fibrosis. The thing is that Gilead doesn't want to hinge its entire future on selonsertib. It also wants to establish a stronghold in NASH. Therefore, it has been creating a flurry of deals with many other NASH biotechs. This week is no different, because it has chosen to advance another early stage program that deals with NASH. This is a partnership that was created